Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $28,684.80 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline sold 2,490 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $28,684.80. Following the completion of the transaction, the chief financial officer now owns 74,595 shares of the company’s stock, valued at $859,334.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Travere Therapeutics Trading Down 4.7 %

NASDAQ:TVTX opened at $12.24 on Thursday. The company has a market capitalization of $936.24 million, a P/E ratio of -5.83 and a beta of 0.71. The stock’s 50 day moving average price is $9.48 and its 200 day moving average price is $7.92. The company has a debt-to-equity ratio of 24.96, a quick ratio of 2.99 and a current ratio of 3.04. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $14.07.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). The business had revenue of $54.12 million during the quarter, compared to the consensus estimate of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. On average, research analysts forecast that Travere Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently bought and sold shares of TVTX. Forefront Analytics LLC lifted its position in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after buying an additional 1,237 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Travere Therapeutics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after purchasing an additional 1,557 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in Travere Therapeutics by 3.8% during the second quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company’s stock worth $626,000 after purchasing an additional 2,774 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Travere Therapeutics by 10.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock valued at $240,000 after purchasing an additional 2,948 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Travere Therapeutics by 8.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 50,178 shares of the company’s stock valued at $387,000 after purchasing an additional 3,754 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TVTX. Wedbush raised their price objective on shares of Travere Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Bank of America raised their target price on Travere Therapeutics from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. HC Wainwright upped their price target on Travere Therapeutics from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, September 6th. Barclays raised their price objective on Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Travere Therapeutics from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.